Profile
Dr. Mark J.
Poznansky is President & Chief Executive Officer at Ontario Genomics Institute (Private Equity).
Dr. Poznansky has been at OGI since 2010.
Previously he ran his own consultancy group offering a range of services including program reviews, strategic planning, change management and leadership training to clients in government, hospitals, universities and the private sector.
Before that, he was President and Scientific Director of Robarts Research Institute (London, Ontario), where during his tenure, from 1993 to 2007, the institute increased its staff from 100 to over 600, increased its annual research funding from $10 million to over $40 million, and developed a reputation for business development spinning out seven different companies, including Viron Therapeutics, where Dr. Poznansky served as President and CEO.
He also served on the Merck USA Scientific Advisory Leadership Team for three years.
Prior to that, he was Associate Dean of Medicine for Research at the University of Alberta.
He has held faculty positions at University of Western Ontario, University of Alberta and was a lecturer at Harvard University.
Dr. Poznansky earning his bachelor's degree and PhD at McGill University, Dr. Poznansky completed postdoctoral training at Harvard Medical School.
Former positions of Mark J. Poznansky
| Companies | Position | End |
|---|---|---|
Medical Discovery Management Corp.
 Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Director/Board Member | 2007-10-31 |
Robarts Research Institute
 Robarts Research Institute Miscellaneous Commercial ServicesCommercial Services Robarts Research Institute engages in the provision of medical research facilities for investigating various diseases such as diabetes, heart and stroke, Alzheimer's, and cancer diseases. The company was founded by Henry Barnett in 1986 and is headquartered in London, Canada. | President | - |
MedTech Partners, Inc.
 MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Director/Board Member | 2006-10-04 |
| VICAPSYS LIFE SCIENCES, INC. | Founder | - |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Corporate Officer/Principal | - |
Training of Mark J. Poznansky
| McGill University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VICAPSYS LIFE SCIENCES, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
MedTech Partners, Inc.
MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Finance |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Medical Discovery Management Corp.
Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Finance |
Robarts Research Institute
Robarts Research Institute Miscellaneous Commercial ServicesCommercial Services Robarts Research Institute engages in the provision of medical research facilities for investigating various diseases such as diabetes, heart and stroke, Alzheimer's, and cancer diseases. The company was founded by Henry Barnett in 1986 and is headquartered in London, Canada. | Commercial Services |
Ontario Genomics Institute (Private Equity)
 Ontario Genomics Institute (Private Equity) Investment ManagersFinance Ontario Genomics Institute (Private Equity) is a Venture Capital firm in UK. The firm was founded in 2001. The firm is headquartered in London. | Finance |
- Stock Market
- Insiders
- Mark J. Poznansky
